Its overexpression in gliomas, particularly in GBM, is strongly associated with poor prognosis, higher tumor grade, and resistance to treatment, positioning GRP78 as a compelling target for innovative therapeutic approaches. The gene discussed is HSPA5; the disease is central nervous system cancer.